ADME

ADME (Absorption, Distribution, Metabolism, and Excretion) studies are conducted during the early discovery, lead optimisation, and preclinical development phases. These testing results are to provide information for characterisation and ranking of the compounds based on their properties, and to predict their fate after administration into the human body. At clinical development, the same information related to pharmacokinetics (PK) and pharmacodynamics (PD), is collected to enable and confirm effective use of the candidate drugs.

In the lead optimization or ADME predication stage of a drug-discovery program, comprehensive in vitro ADME profiling needs to be complimented with animal experiments to provide deeper insights into drug metabolism and pharmacokinetics (DMPK). All of the ADME screening and properties validation services in our experimental platform include metabolic profiling, stability, metabolite identification, bioavailability screens, CYP450 inhibition and induction assays, drug-drug-interactions, quantitative bioanalysis, drug transporters, etc.

In vitro ADME and DMPK Services
in vitro metabolism	Cytochrome P450 and UGT Reaction Phenotyping Cytochrome P450 Induction Cytochrome P450 Inhibition Cytochrome P450 Ki Hepatocyte Stability Low Clearance HµREL Co-culture Assay Low Clearance Hepatocyte Stability Hepatic Uptake Metabolite Profiling and Identification Microsomal Binding Microsomal Stability Plasma Stability PXR and AhR Nuclear Receptor Activation S9 Stability Time Dependent Inhibition (IC50 Shift) Time Dependent Inhibition (kinact/KI ) Time Dependent Inhibition (single point) UGT Inhibition Monoamine Oxidase Inhibition Monoamine Oxidase Reaction Phenotyping Carboxylesterase Inhibition Carboxylesterase Reaction Phenotyping Aldehyde Oxidase Reaction Phenotyping

In vitro ADME and DMPK Services

in vitro metabolism

Cytochrome P450 and UGT Reaction Phenotyping
Cytochrome P450 Induction
Cytochrome P450 Inhibition
Cytochrome P450 Ki
Hepatocyte Stability
Low Clearance HµREL Co-culture Assay
Low Clearance Hepatocyte Stability
Hepatic Uptake
Metabolite Profiling and Identification
Microsomal Binding
Microsomal Stability
Plasma Stability

PXR and AhR Nuclear Receptor Activation
S9 Stability
Time Dependent Inhibition (IC50 Shift)
Time Dependent Inhibition (kinact/KI )
Time Dependent Inhibition (single point)
UGT Inhibition
Monoamine Oxidase Inhibition
Monoamine Oxidase Reaction Phenotyping
Carboxylesterase Inhibition
Carboxylesterase Reaction Phenotyping
Aldehyde Oxidase Reaction Phenotyping

In vitro ADME and DMPK Services
in vitro permeability and transporters	PAMPA Caco-2 Permeability MDCK-MDR1 Permeability P-gp Substrate Identification BCRP Substrate Identification Human SLC Transporter Substrate Identification Human MRP Transporter Substrate Identification Preclinical Hepatic Oatp Uptake Transporter Substrate Identification P-gp Inhibition BCRP Inhibition Human SLC Transporter Inhibition BSEP and MRP Inhibition Preclinical Hepatic Oatp Uptake Transporter Inhibition Other transporter assays
physico-chemical property measurements	pH/Solubility Profiling Compound Stability Log D
in vitro protein binding	Brain Tissue Binding Plasma Protein Binding Whole Blood Binding Blood to Plasma Ratio

Our instrument and detective systems include SFC, HPLC, RP LC, UPC^2, UPLC, GC, ELSD, MS, CAD Detection, PDA/UV, NMR, Accurate Mass MS, etc. ADME services provided by CD ComputaBio maintain and comply with regulatory guidelines, providing constant confidence in the data. We are focusing on offering cost-effective, high-quality, reproducible data and flexible solutions with fast turnaround times. Be our partner to advance your drug discovery and development projects.

Related Platform:

Online Inquiry